@article{3121655,
    title = "Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis",
    author = "Makavos, G. and Ikonomidis, I. and Andreadou, I. and Varoudi, M. and Kapniari, I. and Loukeri, E. and Theodoropoulos, K. and Pavlidis, G. and Triantafyllidi, H. and Thymis, J. and Parissis, J. and Tsoumani, M. and Rafouli-Stergiou, P. and Katsimbri, P. and Papadavid, E.",
    journal = "Canadian Journal of Cardiology",
    year = "2020",
    volume = "36",
    number = "1",
    pages = "100-111",
    publisher = "HANLEY & BELFUS-ELSEVIER INC",
    issn = "0828-282X",
    doi = "10.1016/j.cjca.2019.06.021",
    keywords = "carbonyl derivative;  cyclosporine;  interleukin 17;  malonaldehyde;  methotrexate;  secukinumab;  biological marker;  IL17A protein, human;  immunosuppressive agent;  interleukin 17;  monoclonal antibody;  secukinumab, adult;  arterial stiffness;  Article;  comparative study;  controlled study;  coronary flow reserve;  diastole;  female;  heart left ventricle function;  heart performance;  human;  major clinical study;  male;  myocardial disease;  oxidative stress;  Psoriasis Area and Severity Index;  psoriasis vulgaris;  psoriatic arthritis;  pulse wave;  blood;  brachial artery;  diagnostic imaging;  echocardiography;  heart left ventricle function;  heart ventricle;  middle aged;  pathophysiology;  physiology;  procedures;  prognosis;  psoriasis;  randomized controlled trial, Antibodies, Monoclonal, Humanized;  Biomarkers;  Brachial Artery;  Cyclosporine;  Echocardiography;  Female;  Heart Ventricles;  Humans;  Immunosuppressive Agents;  Interleukin-17;  Male;  Methotrexate;  Middle Aged;  Prognosis;  Psoriasis;  Pulse Wave Analysis;  Vascular Stiffness;  Ventricular Function, Left",
    abstract = "Background: Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. Methods: A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. Results: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. Conclusions: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function. © 2019 Canadian Cardiovascular Society"
}